SEC Tracker
Get the app

Context Therapeutics CNTX

Context Therapeutics reports Q3 2026 results and pipeline updates

Context Therapeutics (CNTX) filed an 8-K with the SEC on Nov 10, 2026, 4:24 pm ET. Source: the filing on SEC EDGAR.

Item 7.01 Investor disclosure, Item 8.01 Other events

Form
8-K
Filed
Importance
Notable
  1. CTIM-76 showed 22% confirmed ORR and 56% DCR in PROC patients
  2. Cash and cash equivalents of $34.4 million as of September 30, 2026
  3. Dose escalation to 420 µg every three weeks is ongoing
  4. Phase 1b initiation expected in Q1 2027

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Context Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.